Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Selective SMARCA2 |
Target |
Mechanism SMARCA2 inhibitors(Probable global transcription activator SNF2L2 inhibitors), SMARCA4 inhibitors(Transcription activator BRG1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Preclinical | US | 17 Apr 2024 | |
Non-Small Cell Lung Cancer | Preclinical | US | 17 Apr 2024 | |
Colorectal Cancer | Discovery | US | 17 Apr 2024 | |
Endometrial Carcinoma | Discovery | US | 17 Apr 2024 |